Blue Trust Inc. Trims Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Blue Trust Inc. reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 56.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 291 shares of the company’s stock after selling 374 shares during the period. Blue Trust Inc.’s holdings in Medpace were worth $97,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. R Squared Ltd acquired a new position in Medpace in the 4th quarter valued at about $30,000. Stone House Investment Management LLC acquired a new position in Medpace in the 3rd quarter valued at about $33,000. Ashton Thomas Securities LLC acquired a new position in Medpace in the 3rd quarter valued at about $37,000. Capital Performance Advisors LLP acquired a new position in Medpace in the 3rd quarter valued at about $46,000. Finally, True Wealth Design LLC increased its position in Medpace by 16,800.0% in the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after acquiring an additional 168 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $381.44.

Medpace Trading Down 1.2 %

NASDAQ MEDP opened at $340.78 on Friday. The business’s 50 day moving average is $343.13 and its two-hundred day moving average is $347.20. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77. The stock has a market capitalization of $10.38 billion, a price-to-earnings ratio of 26.98, a PEG ratio of 3.81 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.